SAN RAMON, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Cooper Companies (Nasdaq: COO) announced today that it will hold its next annual meeting of stockholders on Tuesday, March 19, 2024. Stockholders of record as of the close of business on January 24, 2024, will be eligible to vote on matters presented in the Company's proxy statement, including electing its slate of directors.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women’s health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies (“Cooper”) has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com.
Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
ir@cooperco.com
| Last Trade: | US$82.27 |
| Daily Change: | -0.65 -0.78 |
| Daily Volume: | 1,225,101 |
| Market Cap: | US$16.420B |
March 06, 2025 December 17, 2024 December 05, 2024 September 03, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
